Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Free Fatty Acid Receptor 4 (FFAR4), also known as GPR120, is a G protein-coupled receptor that functions as a nutrient sensor for medium and long-chain fatty acids. It is highly expressed in enteroendocrine cells, pancreatic cells, and adipose tissue, playing a key role in metabolic regulation, insulin sensitization, and anti-inflammatory processes. Activation of FFAR4 by ligands like omega-3 fatty acids promotes insulin sensitivity, stimulates GLP-1 secretion, and attenuates inflammation, making it a therapeutic target for type II diabetes, obesity, and cardiovascular disease.
Activation of FFAR4 by agonists leads to Gq/11-mediated and β-arrestin‑2-mediated signaling, resulting in various downstream effects such as increased insulin sensitivity, GLP-1 secretion, and anti-inflammatory responses.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Free Fatty Acid Receptor 4 (FFAR4).